Intralesional 5% Dextrose Injection: Ultrasound-guided 5% dextrose injection will be applied to the supraspinatus enthesis and additionally into the partial tear lesion using the peppering technique. A volume of 0.1-0.2 cc will be administered to each point. The treatment will consist of three sessions performed at 21-day intervals.
Perilesional 5% Dextrose Injection: Ultrasound-guided 5% dextrose injection will be applied to the supraspinatus enthesis and additionally around the partial tear lesion using the peppering technique. A volume of 0.1-0.2 cc will be administered to each point. The treatment will consist of three sessions performed at 21-day intervals.
Study summary
This prospective, randomized, double-blind controlled clinical trial aims to compare the clinical and ultrasonographic outcomes of intralesional and perilesional 5% dextrose injection in patients with partial rotator cuff tears. Eligible participants will be randomized into two parallel groups. Both groups will receive ultrasound-guided 5% dextrose injection to the supraspinatus enthesis. In addition, one group will receive intralesional 5% dextrose injection, while the other group will receive perilesional 5% dextrose injection using the peppering technique. Injections will be performed in three treatment sessions at 21-day intervals. All participants will receive a home-based exercise program after completion of the injection treatments. Clinical outcomes will be assessed at baseline, 9 weeks, and 12 weeks after treatment, and ultrasonographic outcomes will be assessed at baseline and 12 weeks.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Diagnosis of partial rotator cuff tear by a specialist physician after appropriate clinical examination and imaging evaluation
* Shoulder pain and functional limitation lasting for at least 3 months
* Clinically confirmed shoulder impingement findings, defined as at least one positive test among Neer, Hawkins-Kennedy, or painful arc tests
* Age between 18 and 75 years
* Ability to comply with the study procedures and attend follow-up visits regularly
* Willingness to participate in the study and provide written informed consent
Exclusion Criteria:
* Advanced cognitive impairment or dementia preventing reliable completion of questionnaires
* Refusal to participate in the study or inability to provide informed consent
* Full-thickness rotator cuff tear
* Major tendon pathology other than the supraspinatus tendon, such as full-thickness subscapularis tear or biceps tendon rupture
* Advanced acromioclavicular joint osteoarthritis, marked impingement, or marked adhesive capsulitis
* Advanced glenohumeral joint arthritis
* Active infection, cellulitis, or dermatologic lesion at the injection site
* Bleeding diathesis or anticoagulant use
* Known allergy or intolerance to dextrose injection
* Intra-articular shoulder injection, including steroid, platelet-rich plasma, or prolotherapy, within the last 3 months
* Previous shoulder surgery
* Uncontrolled diabetes mellitus, defined as HbA1c \>8.5%, or severe endocrine or metabolic disorder
* Immunosuppression or active infection
* Rheumatologic shoulder involvement
* Neurological disease affecting shoulder movements
* Pregnancy
* Active malignancy
Primary outcome measure(s)
Change in Shoulder Pain Intensity Assessed by Numeric Rating Scale — Baseline, 9 weeks, and 12 weeks after treatment Shoulder pain intensity will be assessed using the Numeric Rating Scale. Night pain, worst daytime shoulder pain, and average shoulder pain will be evaluated on a 0-10 scale, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity.
Trial sites (1)
Facility
City
Region
Status
Ankara Bilkent City Hospital, Physical Medicine and Rehabilitation Hospital
Ankara
Turkey (Türkiye)
Recruiting
More Ankara City Hospital Bilkent trials in Turkey
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.